Clinical Pipeline
A Platform Built
for Scale.
>2.6M1
annual patients across target oncology indications
>$0B
Commercial Opportunity
0
Development Programs
Preclinical
Phase 1
Phase 2
Phase 3
Next Milestone
High-Grade Glioma4
Phase 2 Completed>$1.0B
31.3 vs 24.7 mo median OS
Head & Neck Cancer2
Randomized Phase 2 Ongoing$1.5B
Prior Phase 1/2: 36% lower SOM incidence vs historical comparator
Randomized Phase 2 OngoingPrior Phase 1/2: 36% lower SOM incidence vs historical comparator
2027
Rectal Cancer
Enrolling Phase 2$2.3B
NCI-funded evaluation in chemoradiation
Anal Carcinoma21
Phase 1/2 Enrollment CompleteIn Colorectal
61% Reduction in Severe GI Toxicity vs Historical Control
Phase 1/2 Enrollment Complete61% Reduction in Severe GI Toxicity vs Historical Control
2027
Gynecological Cancers
PreclinicalEmerging
Preclinical activity in combination with carboplatin
Gynecological Cancers
PreclinicalPreclinical activity in combination with carboplatin
Next-Gen Compounds
Preclinical R&DPipeline Expansion
BMX-201 / BMX-202
Next-Gen Compounds
Preclinical R&DBMX-201 / BMX-202
Anticipated Development Milestones
Timing and development plans are subject to clinical results, regulatory feedback, funding, and other factors.
2026
- Final data readout – Anal Cancer
2027
- Type B FDA Meeting (Glioma)
- Planned Phase 3 study (HGG)
- Final Phase 2 data (H&N)
- Type B FDA meeting (H&N)
- CMC: Phase 3 readiness (H&N)
- Final Phase 2 data (Colorectal)
2028
- Potential/planned Phase 3 (H&N)
- Prepare Rolling NDA (H&N)
- Potential/planned Phase 3 (Colorectal)